Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Medicine

Background:

• Histamine selectively targets H3 receptors, potentially inhibiting neurogenic edema crucial in migraine.
• Understanding histamine's role in migraine pathophysiology is key to developing new treatments.

Purpose of the Study:

• To assess subcutaneous histamine's efficacy for migraine prophylaxis.
• To compare histamine's effectiveness against oral topiramate, a standard migraine treatment.

Main Methods:

• A 12-week double-blind trial involved 90 migraine patients.
• Subcutaneous histamine (1-10 ng twice weekly) was compared to oral topiramate (100 mg daily).
• Key outcomes included headache intensity, frequency, duration, medication use, and disability assessment.

Main Results:

• Both histamine and topiramate groups showed significant symptom improvement within one month.
• Statistically significant reductions observed: headache frequency (50%), disability (75%), pain intensity (51%), attack duration (45%), and rescue medication use (52%).

Conclusions:

• Subcutaneous histamine and oral topiramate are effective for migraine prophylaxis.
• Subcutaneous histamine presents a promising, novel therapeutic alternative for patients with resistant migraines.